Editas Medicine Inc (EDIT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $334.92M
Last updated: Nov 17, 2026 at 11:05 AM ET
Editas Medicine Inc (EDIT) Earnings: Report Dates and Results
Editas Medicine (EDIT) is confirmed to report earnings on Mar 8, 2027, after the close. In the quarter ended Sep 30, 2026, Editas Medicine reported EPS of -$0.15, above the -$0.21 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
EDIT has a confirmed report date of Mar 8, 2027, after the close.
EDIT Earnings Call
The latest EDIT earnings call transcript on file is labeled 2024Q2.
Read the 2024Q2 transcriptEarnings History
Of the 39 quarters below that had an estimate, EDIT beat 22, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $10.37M, up 37.5% from $7.54M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.15 | -$0.21 | -$0.25 - -$0.19 | +28.57% | Beat | N/A | 7 | 6 up, 0 down | Nov 9, 2026 | $10.37M |
| Jun 30, 2026 | -$0.15 | -$0.30 | -$0.32 - -$0.24 | +50.00% | Beat | N/A | 7 | 1 up, 1 down | Aug 5, 2026 | $11.89M |
| Mar 31, 2026 | -$0.26 | -$0.24 | -$0.30 - -$0.16 | -8.33% | Miss | N/A | 3 | 2 up, 0 down | May 5, 2026 | N/A |
| Dec 31, 2025 | -$0.06 | -$0.23 | -$0.34 - $0.08 | +73.94% | Beat | N/A | 6 | 1 up, 1 down | Mar 9, 2026 | $29.40M |
| Sep 30, 2025 | -$0.28 | -$0.38 | -$0.62 - -$0.29 | +26.32% | Beat | N/A | 6 | 2 up, 2 down | Nov 10, 2025 | $7.54M |
| Jun 30, 2025 | -$0.32 | -$0.38 | -$0.46 - -$0.29 | +15.79% | Beat | N/A | 11 | 4 up, 2 down | Aug 12, 2025 | $3.58M |
| Mar 31, 2025 | -$0.92 | -$0.59 | -$0.84 - -$0.41 | -55.93% | Miss | N/A | 10 | 2 up, 4 down | May 12, 2025 | N/A |
| Dec 31, 2024 | -$0.55 | -$0.33 | -$0.87 - $0.10 | -67.38% | Miss | N/A | 13 | 5 up, 2 down | Mar 5, 2025 | N/A |
| Sep 30, 2024 | -$0.75 | -$0.77 | -$0.96 - -$0.13 | +2.60% | Beat | N/A | 18 | 1 up, 0 down | Nov 4, 2024 | N/A |
| Jun 30, 2024 | -$0.82 | -$0.71 | -$0.84 - -$0.46 | -15.49% | Miss | N/A | 17 | 0 up, 0 down | Aug 7, 2024 | N/A |
| Mar 31, 2024 | -$0.76 | -$0.64 | -$1.09 - -$0.44 | -18.75% | Miss | N/A | 15 | 0 up, 0 down | May 8, 2024 | $1.14M |
| Dec 31, 2023 | -$0.23 | -$0.54 | -$0.75 - $0.21 | +57.41% | Beat | N/A | 15 | 1 up, 0 down | Feb 28, 2024 | $60.05M |
| Sep 30, 2023 | -$0.55 | -$0.58 | -$0.83 - -$0.45 | +5.17% | Beat | N/A | 16 | 1 up, 0 down | Nov 3, 2023 | $5.34M |
| Jun 30, 2023 | -$0.56 | -$0.77 | -$0.93 - -$0.52 | +27.27% | Beat | N/A | 16 | 0 up, 0 down | Aug 2, 2023 | $2.89M |
| Mar 31, 2023 | -$0.71 | -$0.78 | -$0.96 - -$0.51 | +8.97% | Beat | N/A | 17 | 1 up, 0 down | May 5, 2023 | $9.85M |
| Dec 31, 2022 | -$0.88 | -$0.81 | -$1.00 - -$0.61 | -8.64% | Miss | N/A | 17 | 0 up, 0 down | Feb 22, 2023 | $13.35M |
| Sep 30, 2022 | -$0.81 | -$0.85 | -$1.01 - -$0.72 | +4.71% | Beat | N/A | 16 | 0 up, 0 down | Nov 2, 2022 | N/A |
| Jun 30, 2022 | -$0.78 | -$0.80 | -$0.93 - -$0.72 | +2.50% | Beat | N/A | 14 | 0 up, 0 down | Aug 3, 2022 | $6.36M |
| Mar 31, 2022 | -$0.74 | -$0.79 | -$0.91 - -$0.69 | +6.33% | Beat | N/A | 13 | 1 up, 0 down | May 4, 2022 | N/A |
| Dec 31, 2021 | -$0.61 | -$0.72 | -$0.91 - -$0.58 | +15.28% | Beat | N/A | 14 | 0 up, 0 down | Feb 24, 2022 | N/A |
| Sep 30, 2021 | -$0.57 | -$0.81 | -$0.93 - -$0.70 | +29.63% | Beat | -575.0% | 14 | N/A | Nov 8, 2021 | $6.20M |
| Jun 30, 2021 | -$0.81 | -$0.81 | -$0.94 - -$0.69 | 0.00% | In line | N/A | 11 | N/A | Aug 4, 2021 | $379000 |
| Mar 31, 2021 | -$0.86 | -$0.71 | -$0.92 - -$0.61 | -21.13% | Miss | N/A | 11 | N/A | May 5, 2021 | $6.50M |
| Dec 31, 2020 | -$1.00 | -$0.74 | -$0.84 - -$0.67 | -35.14% | Miss | N/A | 8 | N/A | Feb 25, 2021 | $27.89M |
| Sep 30, 2020 | $0.12 | -$0.63 | -$0.81 - -$0.47 | +119.05% | Beat | N/A | 9 | N/A | Nov 5, 2020 | $62.84M |
| Jun 30, 2020 | -$0.43 | -$0.82 | -$0.96 - -$0.62 | +47.56% | Beat | N/A | 9 | N/A | Aug 6, 2020 | N/A |
| Mar 31, 2020 | -$0.69 | -$0.79 | -$0.93 - -$0.64 | +12.66% | Beat | N/A | 8 | N/A | May 7, 2020 | N/A |
| Dec 31, 2019 | -$0.74 | $0.06 | N/A | N/A | N/A | N/A | N/A | N/A | Feb 26, 2020 | $12.28M |
| Sep 30, 2019 | -$0.66 | -$0.73 | N/A | +9.59% | Beat | N/A | N/A | N/A | Nov 12, 2019 | $3.85M |
| Jun 30, 2019 | -$0.69 | -$0.62 | N/A | -11.29% | Miss | N/A | N/A | N/A | Aug 6, 2019 | $2.33M |
| Mar 31, 2019 | -$0.60 | -$0.64 | N/A | +6.25% | Beat | N/A | N/A | N/A | May 7, 2019 | $2.07M |
| Dec 31, 2018 | -$0.52 | -$0.32 | N/A | -62.50% | Miss | N/A | N/A | N/A | Feb 28, 2019 | N/A |
| Sep 30, 2018 | -$0.32 | -$0.81 | -$0.91 - -$0.38 | +60.49% | Beat | N/A | 8 | N/A | Nov 7, 2018 | $14.52M |
| Jun 30, 2018 | -$0.82 | -$0.66 | -$0.74 - -$0.44 | -24.24% | Miss | N/A | 7 | N/A | Aug 6, 2018 | $7.37M |
| Mar 31, 2018 | -$0.67 | -$0.80 | -$0.92 - -$0.72 | +16.25% | Beat | N/A | 7 | N/A | May 3, 2018 | $3.93M |
| Dec 31, 2017 | -$0.84 | -$0.78 | -$1.36 - -$0.52 | -7.69% | Miss | N/A | 7 | N/A | Mar 6, 2018 | $3.67M |
| Sep 30, 2017 | -$0.64 | -$0.63 | -$0.75 - -$0.48 | -1.59% | Miss | N/A | 6 | N/A | Nov 7, 2017 | $6.28M |
| Jun 30, 2017 | -$0.65 | -$0.57 | -$1.01 - -$0.52 | -14.04% | Miss | N/A | 5 | N/A | Aug 9, 2017 | $3.10M |
| Mar 31, 2017 | -$0.85 | -$0.77 | -$0.77 - -$0.33 | -10.39% | Miss | N/A | 4 | N/A | May 15, 2017 | $682000 |
| Dec 31, 2016 | -$1.10 | -$0.62 | N/A | -77.42% | Miss | N/A | N/A | N/A | Mar 7, 2017 | $898000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.58, after -$2.88 the year before. It was -$3.03 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.58 | N/A |
| Dec 31, 2024 | -$2.88 | N/A |
| Dec 31, 2023 | -$2.05 | N/A |
| Dec 31, 2022 | -$3.21 | N/A |
| Dec 31, 2021 | -$2.85 | N/A |
| Dec 31, 2020 | -$2.00 | N/A |
| Dec 31, 2019 | -$2.69 | N/A |
| Dec 31, 2018 | -$2.33 | N/A |
| Dec 31, 2017 | -$2.98 | N/A |
| Dec 31, 2016 | -$3.03 | N/A |
Earnings Calls
The only earnings call listed below, 2024Q2 for the period ended Jun 30, 2024, runs about 7,900 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q2 | Jun 30, 2024 | 7,883 | 18 |
2024Q2 Earnings Call
Opening remarks
Cristi Barnett Corporate Communications and Investor Relations Thank you, Britney. Good morning, everyone and welcome to our second quarter 2024 conference call. Earlier this morning, we issued a press release providing our financial results and recent corporate updates. A replay of today’s call will be available in the Investors section of our website approximately two hours after its completion. After our prepared remarks, we will open the call for Q&A. As a reminder, various remarks that we make during this call about the company’s future expectations, plans and prospects constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including those discussed in the Risk Factors section of our most recent Annual Report on Form 10-K, which is on file with the SEC, as updated by our subsequent filings. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change. Now, I will turn the call over to our CEO, Gilmore O’Neill.
Gilmore O’Neill CEO Thanks, Cristi and good morning everyone. Thank you for joining us today on Editas’ second quarter 2024 earnings call. With me today are four members of the Editas executive team, our Chief Medical Officer, Baisong Mei; our Chief Financial Officer, Erick Lucera; our Chief Scientific Officer, Linda Burkly; and our Chief Commercial and Strategy Officer, Caren Deardorf. Because it is summertime, we are going to keep today’s prepared remarks brief and leave more time to take your questions. Let me start by saying that we are pleased with Editas’ momentum and progress in the second quarter of 2024 as we pursue Editas’ goal to deliver life-changing medicines to patients with untreatable or undertreated genetic diseases and to position Editas as a leader in in-vivo programmable gene editing. Three pillars underpin our strategy. The first of those pillars is to drive reni-cel, a gene edited cell therapy for hemoglobinopathies, formerly known as EDIT-301, toward BLA and commercialization. Second, to build a differentiated in-vivo editing pipeline and third, to increase business development activities with a particular focus on monetizing our very strong IP. At the start of 2024, we announced the following 2024 objectives. For reni-cel, we will provide a clinical update from the RUBY trial for severe sickle cell disease and the EdiTHAL trial for transfusion-dependent beta thalassemia in mid-2024 and by year-end 2024.
Frequently Asked Questions About EDIT
When is Editas Medicine's next earnings date?
Editas Medicine's next earnings report is confirmed for Mar 8, 2027, after the close.
Did EDIT beat earnings estimates last quarter?
Yes. Editas Medicine reported EPS of -$0.15 for the quarter ended Sep 30, 2026, above the -$0.21 estimate, a 28.57% surprise.
What EPS do analysts expect from EDIT next quarter?
The consensus EPS estimate for Editas Medicine for the quarter ending Dec 31, 2026 is -$0.19 from 14 analysts, with estimates from -$0.27 to -$0.08.
How often does EDIT beat earnings estimates?
Editas Medicine beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +7.87%.
Does EDIT report before or after the market opens?
Editas Medicine is confirmed to report on Mar 8, 2027, after the market closes.
EDIT pages: Overview, Earnings, Forecast, Financials, Competitors